INTRODUCTION: The aim of this study was to investigate the association of donor CD4(+) T cells expressing CD62L with transplant outcomes. MATERIALS AND METHODS: We report a prospective analysis of 31 patients who were treated with a Bu/Cy regimen, followed by unmanipulated blood and marrow transplantation. RESULTS: Median number (range) of CD4(+)CD62L(+), CD4(+)CD45RA(+)CD62L(+), and CD4(+)CD45RO(+)CD62L(+) cells infused were 0.31(0.05-1.10)x10(8)/kg, 0.22(0.03-0.95)x 10(8)/kg, and 0.17(0.01-0.81)x10(8)/kg, respectively. The incidence of grades II to IV aGVHD was 36%. In a multivariate analysis, infusion of >0.22 x 10(8) CD4(+)CD45RA(+)CD62L(+) cells infused/kg increased the risk of grades II to IV aGVHD (HR = 4.741, 95% CI = 1.037-21.662, P = 0.045). Thirteen of 31 patients experienced cGVHD, the risk of cGVHD was increased in patients receiving >0.45 x 10(8) CD4(+)CD45RA(+) cells infused/kg (HR = 4.614, 95% CI = 1.265-16.829, P = 0.021). CONCLUSION: Our results suggest that a high cell dose of CD4(+)CD45RA(+)CD62L(+) cells increase the incidence of grades II-IV aGVHD. A high number of CD4(+)CD45RA(+) cells infused were associated with increased risk of cGVHD in our transplant settings.
INTRODUCTION: The aim of this study was to investigate the association of donorCD4(+) T cells expressing CD62L with transplant outcomes. MATERIALS AND METHODS: We report a prospective analysis of 31 patients who were treated with a Bu/Cy regimen, followed by unmanipulated blood and marrow transplantation. RESULTS: Median number (range) of CD4(+)CD62L(+), CD4(+)CD45RA(+)CD62L(+), and CD4(+)CD45RO(+)CD62L(+) cells infused were 0.31(0.05-1.10)x10(8)/kg, 0.22(0.03-0.95)x 10(8)/kg, and 0.17(0.01-0.81)x10(8)/kg, respectively. The incidence of grades II to IV aGVHD was 36%. In a multivariate analysis, infusion of >0.22 x 10(8) CD4(+)CD45RA(+)CD62L(+) cells infused/kg increased the risk of grades II to IV aGVHD (HR = 4.741, 95% CI = 1.037-21.662, P = 0.045). Thirteen of 31 patients experienced cGVHD, the risk of cGVHD was increased in patients receiving >0.45 x 10(8) CD4(+)CD45RA(+) cells infused/kg (HR = 4.614, 95% CI = 1.265-16.829, P = 0.021). CONCLUSION: Our results suggest that a high cell dose of CD4(+)CD45RA(+)CD62L(+) cells increase the incidence of grades II-IV aGVHD. A high number of CD4(+)CD45RA(+) cells infused were associated with increased risk of cGVHD in our transplant settings.
Authors: K M Sullivan; E Agura; C Anasetti; F Appelbaum; C Badger; S Bearman; K Erickson; M Flowers; J Hansen; T Loughran Journal: Semin Hematol Date: 1991-07 Impact factor: 3.851
Authors: Elisha Waldman; Sydney X Lu; Vanessa M Hubbard; Adam A Kochman; Jeffrey M Eng; Theis H Terwey; Stephanie J Muriglan; Theo D Kim; Glenn Heller; George F Murphy; Chen Liu; Onder Alpdogan; Marcel R M van den Brink Journal: Blood Date: 2005-11-15 Impact factor: 22.113
Authors: V Rocha; M V Carmagnat; S Chevret; O Flinois; H Bittencourt; H Esperou; F Garnier; P Ribaud; A Devergie; G Socié; L Dal'Cortivo; J P Marolleau; D Charron; E Gluckman; C Rabian Journal: Exp Hematol Date: 2001-11 Impact factor: 3.084
Authors: H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas Journal: Am J Med Date: 1980-08 Impact factor: 4.965
Authors: M-T Rubio; M Bouillié; N Bouazza; T Coman; H Trebeden-Nègre; A Gomez; F Suarez; D Sibon; A Brignier; E Paubelle; S Nguyen-Khoc; M Cavazzana; O Lantz; M Mohty; S Urien; O Hermine Journal: Leukemia Date: 2016-10-14 Impact factor: 11.528
Authors: Lauren V Schnabel; Christian M Abratte; John C Schimenti; M Julia Bevilaqua Felippe; Jennifer M Cassano; Teresa L Southard; Jessica A Cross; Lisa A Fortier Journal: Regen Med Date: 2014-04-28 Impact factor: 3.806